Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine industry news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
This major milestone advances Numinus’ investigation of its first proprietary psychedelic product, which was developed using a patent-pending technology submitted to the US Patent and Trade Office.
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies
The Company expects to hold a Research & Development event to review these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media.
European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders
Peter Rands, Chief Executive Officer of Small Pharma, said: “We continue to experience rapid maturation both in our corporate profile and the progression of our pipeline of therapeutic candidates
Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market
The Company announces that it has recently received a CAD$2M cash payment from its clinical research work in Australia, which brings Algernon’s current working capital balance to approximately CAD$3.5M. The Company also announces that it has submitted an application to have its common shares listed on the Nasdaq Capital Market.
Levitee Labs Enters into Credit Facility For Up To $12 Million
The company is pleased to report that it has entered into a financing agreement for up to $12 million for further business expansion.
Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton
The Company announced the opening of their Seattle clinic, their sixth in the United States, along with the recent opening of a location in Fredericton, NB, and the imminent opening of a location in Vancouver, BC.